ExpreS2ion appoints new CFO

Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that it has appointed Mr. Keith Alexander as new Chief Financial Officer (CFO). Mr. Alexander brings more than 20 years of corporate banking and strategy consulting experience and will initially be focused on strengthening the Company’s financial strategies and investor relations function. Mr. Alexander will begin his employment on October 1, 2020 and be based out of ExpreS2ion’s headquarters in Hørsholm, Denmark. The appointment of Mr. Alexander follows the strategy transformation announced earlier this year.

Mr. Alexander (44) joins ExpreS2ion with over 20 years of experience in investment markets, investor communications, corporate strategy and business development. He joins ExpreS2ion from Danske Bank Asset Management, where he was responsible for the Fixed Income & Credit Advisory & Product Specialist function. He has held previous positions at Danske Capital as Head of North America, and at J.P. Morgan in New York City as Vice President, Strategy & Business Development, and Vice President, Equity Research. He has an MBA from The Wharton School of the University of Pennsylvania in Philadelphia, PA, USA, and a B.Sc. in Industrial Management with a minor in Biological Sciences from Purdue University in West Lafayette, Indiana, USA.

ExpreS2ion’s CEO Bent Frandsen comments:

“I am very pleased that Keith has decided to join the next stage of ExpreS2ions journey. His experience will be a great asset as we move forward with the strategy transformation we announced in the beginning of 2020. The first order of business is to support with financial aspects in ExpreS2ion’s transformation to a pipeline-driven business model, including all the requirements needed to be ready to exercise our option on AV001.”

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

For further information about ExpreS2ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail:
buf@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.

About Us

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.

Subscribe